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During the ﬁrst trimester of pregnancy fetal trophoblasts invade the maternal decidua,
thereby remodeling the maternal spiral arteries. This process of trophoblast invasion is
very similar to cancer cell invasion, with multiple signaling pathways shared between the
two. Pregnancy-related diseases, e.g., pre-eclampsia, and cancer metastasis start with a
decrease or increase in cellular invasion, respectively. Here, we investigate if ﬁrst trimester
placental explants can be used to identify epigenetic factors associatedwith changes in cel-
lular invasion and their potential use as biomarkers.We show that the outgrowth potential
of ﬁrst trimester explants signiﬁcantly correlates with promoter methylation of PRKCDBP
and MMP2, two genes known to be differentially methylated in both placenta and cancer.
The increase in methylation percentage of placental cells coincides with an increase in
invasion potential. Subsequently, as a non-invasive marker must be detectable in blood,
plasma samples of pregnant and non-pregnant women were analyzed. The MMP2 pro-
moter showed high methylation levels in non-pregnant plasma samples, which decreased
in pregnant plasma samples which also contain placental DNA.The decrease in methylated
plasma DNA during pregnancy is most likely due to the fractional increase in unmethylated
placental DNA. This suggests that the level of unmethylated DNA has the potential to be
used as an invasionmarker, where higher levels of unmethylated DNA indicate a lower inva-
sion potential of trophoblasts. These proof of principle data provide evidence that human
ﬁrst trimester placental explants are an excellent ex vivo model system to identify (epige-
netic) factors and thus potential biomarkers associated with changes in cellular invasion,
e.g., to detect pregnancy-related diseases or cancer metastasis.To identify novel biomark-
ers the next step is to correlate naturally occurring variation in invasion potential to changes
in (epigenetic) factors by genome-wide approaches such as massively parallel sequencing.
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INTRODUCTION
During the ﬁrst trimester of pregnancy fetal trophoblasts invade
the maternal decidua. By invading the decidua the maternal spiral
arteries are remodeled by the invasive trophoblasts. This process
of trophoblast invasion is very similar to cancer cell invasion, with
multiple signaling pathways shared between the two (Ferretti et al.,
2007; Holtan et al., 2009), giving rise to, e.g., migration and inva-
sion of stroma and arteries, epithelial-mesenchymal transition,
heterotypic interactions, and the shedding of particles into the
circulation. Interestingly, multiple pregnancy complications, i.e.,
IUGR (intra-uterine growth restriction) and pre-eclampsia, show
a reduction in trophoblast invasion during ﬁrst trimester (Steegers
et al., 2010).
The fact that trophoblast invasion and cancer cell invasion share
many signaling pathways makes the ﬁrst trimester placenta an
excellent model to study factors involved in either increased or
decreased invasion potential.
The aim of this study is to investigate if the naturally occurring
variation in invasion potential of human ﬁrst trimester placental
explants correlates to changes in epigenetic factors. In the future,
this set up can be used as an ex vivo model system to identify factors
by genome-wide approaches (e.g., massively parallel sequencing),
and thus potential biomarkers associated with changes in cellu-
lar invasion, e.g., to detect pregnancy-related diseases or cancer
metastasis.
Previously, we identiﬁed the STOX1 Y153H SNP to be a sus-
ceptibility allele for pre-eclampsia in Dutch females (Van Dijk
et al., 2005). When the invasion potential of ﬁrst trimester pla-
cental explants was established by measuring the outgrowth of the
explants a signiﬁcant reduction in invasion potential was found in
the placentas homozygous for the Y153H allele (Van Dijk et al.,
2010). This ﬁnding showed that genetic differences can give rise to
measurable changes in outgrowth potential. The study described
here investigates if also epigenetic differences can be detected in
ﬁrst trimester placentas with different invasion potentials. When
this is the case, not only genetic and protein or mRNA expression
differences can function as potential factors, but also epigenetic
differences, increasing the identiﬁcation of novel biomarker panels
by genome-wide approaches.
For testing the use of ﬁrst trimester epigenetic differences
in relation to invasion potential the methylation levels of 10
genes were chosen to study. Eight well-known tumor suppressor
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genes (TP73, RASSF5, RASSF1, APC, DAB2IP, PRKCDBP, WT1,
MORF4L1) were chosen which all were described by Grigoriu
et al. (2011) to be differentially methylated in ﬁrst trimester pla-
centa. From the extensive list of proteins and pathways shared
by cancer cell invasion and trophoblast invasion, e.g., the WNT
signaling pathway, integrins, enzymes, growth factors, and their
receptors (see for overviewsFerretti et al.,2007;Holtan et al.,2009),
two matrix metalloproteinases were chosen to study, MMP9 and
MMP2. Both are found to be expressed in the invasive trophoblast
as well as malignant tumors (Ferretti et al., 2007; Holtan et al.,
2009).
MATERIALS AND METHODS
PLACENTAL DNA SAMPLES
Placental DNA used (n = 32) originates from placental samples
with established outgrowth potential as described previously (Van
Dijk et al., 2010). In short, small fragments of placental villi
from 6 to 9 week gestation were dissected from placenta, placed
on Matrigel and cultured at 3% O2 and 37˚C in serum free
DMEM/F12 media. Simultaneously, small fragments of the same
placentas were kept for DNA isolation. At day 2 and day 4 pic-
tures were taken to measure changes in outgrowth. The explant
outgrowth potentials were measured by taking the difference of
the distance the extravillous trophoblasts migrated between day 2
and day 4. From each placenta at least three explants were grown,
explants that did not show any growth were left out of analyses
because they were either not viable or were not properly dissected.
For the current study only DNA of placentas were used that had
at least two explants with growth.
PLASMA DNA SAMPLES
Simultaneous isolation of DNA and RNA from plasma samples
was performed as described previously (Oudejans et al., 2003)with
modiﬁcations (Go et al., 2007). Pregnant sample collection was
approved by the ethics committee of the VU University Medical
Center. Informed consent was obtained from all women. Isolated
DNA samples (n = 26) were precipitated and concentrated to be
able to use the DNA amount isolated from 1 ml plasma (∼20 ng)
in each reaction. Characteristics of the plasma samples analyzed
can be found in Table 1.
DNA METHYLATION ASSESSMENT
The level of DNA methylation was measured using the OneStep
qMethyl kit (Zymo Research). For use with this assay, 10 primer
pairs were designed within CpG rich (promoter) regions accord-
ing to the OneStep qMethyl kit guidelines. Primer sequences can
be found in Table 2. In brief, to measure methylation percent-
ages 20 ng DNA (or DNA isolated from 1 ml plasma) in duplicate
is placed in a test and a reference reaction mix including primers.
The samples are placed in anABI7300 with the following protocol:
2 h 37˚C; 10 min 95˚C; 50 cycles 30 s 95˚C, 1 min 54˚C, 1 min 72˚C
followed by an dissociation stage to check speciﬁcity of the PCR
products. The Ct values obtained are used to calculateΔCt values
[Ct(test) – Ct(reference)]. From this methylation percentages are
calculated using Methylation%= 100× 2−ΔCt. This calculation is
similar as calculating fold differences in a standard quantitative
PCR assay, except that the fold differences are now expressed as
percentages by multiplying the fold difference by 100. For exam-
ple, a“fold difference”of 0.125 (which represents aΔCt value of 3)
using thismethod gives amethylation percentage of 12.5%,while a
ΔCt of 0 (no difference between reference and test reaction) gives a
fold difference of 1 indicating 100% methylation. Each primer set
used was tested for reaction efﬁciency by measuring dilutions of
fully methylated and unmethylated DNA samples provided with
the kit (Table 3). Secondly, calibrator samples consisting of 0, 35,
65, and 100%methylatedDNAwere run in each experiment. From
these the inter-assay and intra-assay reproducibility was investi-
gated, shown in Tables 4 and 5, respectively. From this it can be
concluded that at low percentages the errors are smaller, and the
assay therefore more sensitive, than at higher levels of methylation.
DATA ANALYSIS
Statistical analysis of the obtained data was carried out with the
GraphPad Prism program. In here, linear regression analysis was
performed for Figures 1A,B and 2B and Table 3. The p values of
the linear regression lines represent the testing of the null hypoth-
esis that the slope is zero, where the p value is calculated from an
F test. Data in Tables 1, 4, and 5 and Figure 2A were obtained
calculating the mean, median, SD, and SE of the mean of the
measurements.
RESULTS
OUTGROWTH CORRELATES WITH DNA METHYLATION
DNA samples of ﬁrst trimester placentas with known outgrowth
potential were used to study the epigenetic status of the promot-
ers of two matrix metalloproteinases (MMP9, MMP2) known
to be involved in both placentation and cancer (Ferretti et al.,
2007), and eight tumor suppressor genes (TP73,RASSF5,RASSF1,
APC, DAB2IP, PRKCDBP, WT1, MORF4L1) known to show
partial DNA methylation in ﬁrst trimester placentas (Grigoriu
et al., 2011). From the 10 genes chosen to study, PRKCDBP
and MMP2 showed a signiﬁcant linear regression, p = 0.017 and
Table 1 | Characteristics of plasma samples analyzed.
Non-pregnant (n =12) Pregnant
Total (n =14) 1stTrimester
(≤90days gestation; n =10)
2ndTrimester
(>90days gestation; n =4)
Age women in years (range) 32.3 (27–40) 34.6 (28–38) 34.4 (29–38) 35.3 (28–38)
Gestational age in days (range) NA 91.6 (42–182) 71.7 (42–86) 141.3 (102–182)
Methylation % (range) 62.5 (0.0–100.0) 33.0 (8.1–53.7) 36.4 (12.5–53.7) 24.5 (8.1–44.3)
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Table 2 | Primer sequences used in OneStep qMethyl kit.
Gene Forward primer (5′–3′) Reverse primer (5′–3′)
TPA73 AAGCGAAAATGCCAACAAAC CACCGACGTACAGCATGGTA
RASSF5 GGTTCTCTTGGGTCGTCCTT TCCAATAGTAGCGGGTACGG
RASSF1 ACCTAGTCCTCGGGAGCTGT ACCTCTGTGGCGACTTCATC
APC AAGCCAGCAACACCTCTCAC AGTACCTGGGAACAGCATCG
DAB2IP TCCGGGGTTAGGTGAGTAGA GCCGAAAATGCCTTTTGTAT
PRKCDBP CGGAGGCTCTGTACCTTCTG GTAAGGAGCTGCCAGGATCA
WT1 ATCGGACACGGGTTTGATTA CTTGGCCACTCGATTCTCTC
MORF4L1 CGGAGAGAGCAGCCTATTGT GGCCATTTTACAACGCACTT
MMP2 CTACGATGGAGGCGCTAATG CGGGGAACTTGATGATGG
MMP9 CATCGTCATCCAGTTTGGTG GAAATAAGTGCGGGCTGAAA
Table 3 | Reaction efficiencies of the primer sets used.
Primer set Slope r2
TP73 1.0040±0.008801 0.9998
RASSF5 0.9948±0.016310 0.9995
RASSF1 0.9864±0.023650 0.9989
APC 0.9736±0.062900 0.9917
DAB2IP 0.9458±0.113500 0.9720
PRKCDBP 0.9981±0.003968 1.0000
WT1 1.0000±0.008441 0.9999
MORF4L1 1.0020±0.008762 0.9998
MMP2 0.9929±0.018690 0.9993
MMP9 0.9980±0.003860 1.0000
The slope value is obtained by analyzing the linear regression of the percentage
of methylated DNA input plotted against the percentage of methylation mea-
sured. The r2 value indicates the goodness of ﬁt of the different percentages of
methylated DNA input on the linear regression line where 1 indicates a perfect
ﬁt.
Table 4 | Inter-assay reproducibility based on three independent
assays.
% Methylated
DNA input
% Methylation measured
Mean (SD) Median Minimum Maximum
0 5.889 (8.095) 2.547 0.000 15.12
35 35.52 (6.276) 36.14 27.35 42.48
65 53.58 (12.65) 56.35 36.17 65.45
100 107.1 (15.42) 100.5 88.66 123.8
p = 0.028, respectively, where the increase in methylation percent-
age coincided with an increase in invasion potential (Figure 1).
The remaining eight genes did not give signiﬁcant changes in
methylation level upon changes in outgrowth potential (data not
shown).
NON-INVASIVE BIOMARKER DETECTION IN BLOOD
To function as a non-invasive marker an (epigenetic) factor must
be detectable in blood. Therefore, methylation of PRKCDBP and
Table 5 | Intra-assay reproducibility showing the positive and negative
errors of percentage methylation measured for the four methylated
DNA input controls in two independent assays.
% Methylation input % Methylation error Mean (SD)
0 Positive 4.426 (2.423)
Negative 3.663 (1.618)
35 Positive 2.851 (0.9235)
Negative 2.621 (0.8695)
65 Positive 8.404 (8.145)
Negative 6.924 (6.308)
100 Positive 12.67 (2.874)
Negative 11.00 (1.805)
FIGURE 1 | Correlation between placental explant outgrowth and
PRKCDBP (A) and MMP2 (B) promoter methylation in first trimester
placenta.
MMP2 was tested in pregnant plasma and compared to non-
pregnant plasma samples. PRKCDBP showed low levels of methy-
lation in both pregnant and non-pregnant samples (data not
shown). The MMP2 promoter showed high methylation levels in
non-pregnant plasma samples, which decreased in ﬁrst trimester
samples and further decreased in second trimester (Figure 2A;
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FIGURE 2 | MMP2 promoter methylation in non-pregnant, first
trimester and second trimester plasma samples (A), and linear
regression of MMP2 methylation percentages plotted against the age
of the women (B). Circles represent mean±SEM.
Table 1). Plotting themethylation percentages of the same samples
versus the age of the women showed a signiﬁcant linear regression
in pregnant women (p = 0.0329), while the linear regression was
not signiﬁcant in non-pregnant women (Figure 2B). In this graph
ﬁrst and second trimester women were combined as the age range
of the second trimester women was not evenly distributed, see also
Table 1.
DISCUSSION
The aim of this study was to investigate if the naturally occurring
variation in invasion potential of human ﬁrst trimester placental
explants correlates to changes in epigenetic factors. Previously, we
showed that genetic differences can give rise to changes in out-
growth potential, as shown for the STOX1 Y153H SNP (Van Dijk
et al., 2010). In this study,we describe the use of ﬁrst trimester pla-
cental explants to identify epigenetic differences associated with
changes in cellular invasion. Increase in methylation of PRKCDBP
and MMP2 in placental cells showed a signiﬁcant linear regres-
sion with increased invasion potential of ﬁrst trimester placental
explants. Increased PRKCDBP methylation levels have frequently
been found in several human malignancies, including colorectal,
lung, breast, and gastric cancers (Xu et al., 2001; Zöchbauer-
Müller et al., 2005; Lee et al., 2008, 2011). Hypermethylation of
the promoter region of this gene causes downregulated expres-
sion correlating with tumor progression (Lee et al., 2011). This is
in accordance with our ﬁndings showing increased methylation
upon increased outgrowth potential of trophoblasts. Except for
the study by Grigoriu et al. (2011) identifying differential methy-
lation of tumor suppressor genes in ﬁrst trimester placenta by
microarray, no other studies have been done on PRKCDBP or
MMP2 methylation in the placenta. MMP2 expression and acti-
vation levels, however, have been repeatedly found to be increased
upon increased trophoblast invasion (Godbole et al., 2011; Onogi
et al., 2011; Williams et al., 2011). The literature on increased
levels and activation of MMP2 upon tumor progression in var-
ious cancer types are numerous, see for a selection of reviews
(Levicar et al., 2003; Overall and Dean, 2006; Qian et al., 2011).
Furthermore, a decreased methylation status of MMP2 in dif-
ferent cancers types has also been found to be associated with
increased tumor invasion (Chernov et al., 2009; Morán et al.,
2012). Therefore, although it would have been expected to ﬁnd
a decrease in methylation of the MMP2 promoter, this was not
seen in this study. This inconsistency might be a good exam-
ple of the main difference between trophoblasts and tumor-
ous cells, i.e., the invasion of trophoblasts is tightly regulated
in a time and place restricted manner. Methylation of MMP2
upon increased invasion potential can be one of these regulatory
mechanisms.
Next, we show that one of the two factors identiﬁed can be
detected in plasma of both pregnant and non-pregnant women.
High MMP2 methylation levels were detected in non-pregnant
plasma DNA samples, which decreased in ﬁrst trimester samples
which also contain placental DNA. A further decrease was seen
in second trimester samples. The increased amount of unmethy-
lated DNA in pregnant plasma compared to non-pregnant plasma
is most likely placental in origin, due to the additional fractional
contribution of unmethylated placenta DNA to plasma during
pregnancy. The additional fractional increase of unmethylated
DNA during the second trimester of pregnancy is consistent
with the knowledge that the invasion capacity of the placen-
tal trophoblasts also decreases (Zhou et al., 1993). This current
methylation pattern seen for MMP2 has been shown before in
the SERPINB5 promoter (Chim et al., 2005). SERPINB5 is a
well-known tumor suppressor gene in which the promoter fur-
thermore showed downregulated methylation in pre-eclamptic
plasma samples. To conclude, the increase in unmethylated DNA
during pregnancy suggests that the level of unmethylated DNA
has the potential to be used as an invasion marker, where higher
levels of unmethylated DNA indicate a lower invasion potential of
trophoblasts.
This proof-of-principle study therefore provides evidence
that it is possible to use human placental explants as an
ex vivo model to identify factors associated with changes in
cellular invasion, e.g., to detect pregnancy-related diseases or
cancer metastasis. This study shows that not only genetic
and protein or mRNA expression differences can function
as potential factors, but also epigenetic differences, increasing
the identiﬁcation of novel biomarker panels by genome-wide
approaches.
It must be noted that within the current setting MMP2
methylation itself is not usable as a cellular invasion marker.
This is due to the high variance of methylation found in non-
pregnant samples compared to the pregnant plasma samples,
as was shown by the linear regression plots of the methyla-
tion percentages versus the age of the women. A linear regres-
sion in methylation versus age can be expected when mea-
suring epigenetic effects, however, this was only the case in
Frontiers in Genetics | Epigenomics February 2012 | Volume 3 | Article 22 | 4
van Dijk et al. Biomarkers from trophoblast invasion variation
pregnant samples. The high variance in non-pregnant women
might be caused by the observation that plasma samples derived
from parous non-pregnant women overall had lower methyla-
tion percentages as nulliparous women. However, the amount
of parous samples in the non-pregnant group is small (n = 4)
and it is not known if the nulliparous women never have been
pregnant.
Another issue that needs to be addressed is the method used
to measure differences in methylation percentage. The current
assay used shows, although within acceptable range at low methy-
lation levels (mean errors around 3%), at higher methylation
percentages mean errors up to almost 13%. Therefore, when by
genome-wide approaches epigenetic factors are being identiﬁed,
the method used to measure methylation differences as potential
biomarkers should be highly sensitive and accurate at all levels
of methylation, which might be achieved by using pyrosequenc-
ing or methylation-speciﬁc single nucleotide primer extension
(MS-SNuPE).
Although MMP2 promoter methylation in the current set-
ting is not usable as a biomarker, it can be envisaged that it
does have the potential to be used in combination with other
biomarkers yet to be identiﬁed. This proof-of-principle study
shows that the described method can be used to identify novel
biomarkers by correlating naturally occurring variation in inva-
sion potential to changes in (epigenetic) factors by genome-wide
approaches such as massively parallel sequencing. Using genome-
wide approaches on naturally occurring variation in invasion
potential of ﬁrst trimester placental explants increases the suc-
cess of identifying primary factors involved in cellular invasion
changes. Especially the ﬁrst trimester placenta is highly informa-
tive as this is the period in which trophoblast invasion starts and
dysfunction in this process will give complications later in preg-
nancy. The same holds for cancer cell invasion; when the ﬁrst
signs of metastasis are recognized early, the success of treatment
highly increases. As non-invasive early detection markers are still
lacking in both pregnancy-related disorders and cancer metastasis
new approaches on the identiﬁcation of novel biomarkers are still
urgently needed.
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